Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey

Guidelines for the diagnosis and management of multiple myeloma 2011

(2011) Jennifer M. Bird et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation

(2011) N. Shah et al.   Hematology-American Society of Hematology Education Program

Multiple myeloma

(2010) J. Blade et al.   ANNALS OF ONCOLOGY

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

(2010) A. Waage et al.   BLOOD

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

(2010) Pierre Wijermans et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations

(2009) Ann Kristin Kvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

(2009) Cyrille Hulin et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

(2009) A Palumbo et al.   LEUKEMIA